| Item Type | Name |
|
Concept
|
Exercise Therapy
|
|
Concept
|
Drug Therapy, Combination
|
|
Concept
|
Treatment Outcome
|
|
Concept
|
Therapeutics
|
|
Concept
|
Combined Modality Therapy
|
|
Concept
|
Drug Therapy
|
|
Concept
|
Thrombolytic Therapy
|
|
Concept
|
Treatment Failure
|
|
Academic Article
|
Comparative Efficacy of Endovascular Revascularization Versus Supervised Exercise Training in Patients With Intermittent Claudication: Meta-Analysis of Randomized Controlled Trials.
|
|
Academic Article
|
Rationale and design for the Vascular Outcomes study of ASA along with rivaroxaban in endovascular or surgical limb revascularization for peripheral artery disease (VOYAGER PAD).
|
|
Academic Article
|
Outcomes in Stable Patients With Previous Atherothrombotic Events Receiving Vorapaxar Who Experience a New Acute Coronary Event (from TRA2°P-TIMI 50).
|
|
Academic Article
|
Platelet Inhibition With Ticagrelor 60 mg Versus 90 mg Twice Daily in the PEGASUS-TIMI 54 Trial.
|
|
Academic Article
|
Effect of the novel thienopyridine prasugrel compared with clopidogrel on spontaneous and procedural myocardial infarction in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction 38: an application of the classification system from the universal definition of myocardial infarction.
|
|
Academic Article
|
Peripheral Revascularization in Patients With Peripheral Artery Disease With Vorapaxar: Insights From the TRA 2°P-TIMI 50 Trial.
|
|
Academic Article
|
Vorapaxar in patients with diabetes mellitus and previous myocardial infarction: findings from the thrombin receptor antagonist in secondary prevention of atherothrombotic ischemic events-TIMI 50 trial.
|
|
Academic Article
|
DECLARE-TIMI 58: Participants' baseline characteristics.
|
|
Academic Article
|
Prasugrel Versus Ticagrelor: Uncertainty Remains.
|
|
Academic Article
|
Efficacy and safety of vorapaxar as approved for clinical use in the United States.
|
|
Academic Article
|
Efficacy and safety of vorapaxar in patients with prior ischemic stroke.
|
|
Academic Article
|
Vorapaxar in patients with peripheral artery disease: results from TRA2{degrees}P-TIMI 50.
|
|
Academic Article
|
American College of Cardiology/American Heart Association/European Society of Cardiology/World Heart Federation universal definition of myocardial infarction classification system and the risk of cardiovascular death: observations from the TRITON-TIMI 38 trial (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis in Myocardial Infarction 38).
|
|
Academic Article
|
Long-term use of ticagrelor in patients with prior myocardial infarction.
|
|
Academic Article
|
Antiplatelet Therapy for Secondary Prevention After Acute Myocardial Infarction.
|
|
Academic Article
|
Primary Stroke Prevention: Medical Therapy Versus Revascularization.
|
|
Academic Article
|
Effect of Losmapimod on Cardiovascular Outcomes in Patients Hospitalized With Acute Myocardial Infarction: A Randomized Clinical Trial.
|
|
Academic Article
|
Long-term dual antiplatelet therapy for secondary prevention of cardiovascular events in the subgroup of patients with previous myocardial infarction: a collaborative meta-analysis of randomized trials.
|
|
Academic Article
|
Ticagrelor for Prevention of Ischemic Events After Myocardial Infarction in Patients With Peripheral Artery Disease.
|
|
Academic Article
|
Efficacy and Safety of Vorapaxar With and Without a Thienopyridine for Secondary Prevention in Patients With Previous Myocardial Infarction and No History of Stroke or Transient Ischemic Attack: Results from TRA 2°P-TIMI 50.
|
|
Academic Article
|
Vorapaxar in patients with coronary artery bypass grafting: Findings from the TRA 2°P-TIMI 50 trial.
|
|
Academic Article
|
Clinical features, use of evidence-based therapies, and cardiovascular outcomes among patients with chronic kidney disease following non-ST-elevation acute coronary syndrome.
|
|
Academic Article
|
Evaluation of a novel antiplatelet agent for secondary prevention in patients with a history of atherosclerotic disease: design and rationale for the Thrombin-Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2 degrees P)-TIMI 50 trial.
|
|
Academic Article
|
Ischaemic risk and efficacy of ticagrelor in relation to time from P2Y12 inhibitor withdrawal in patients with prior myocardial infarction: insights from PEGASUS-TIMI 54.
|
|
Academic Article
|
Prognostic performance of multiple biomarkers in patients with non-ST-segment elevation acute coronary syndrome: analysis from the MERLIN-TIMI 36 trial (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Elevation Acute Coronary Syndromes-Thrombolysis In Myocardial Infarction 36).
|
|
Academic Article
|
Patterns of long-term thienopyridine therapy and outcomes in patients with acute coronary syndrome treated with coronary stenting: Observations from the TIMI-38 Coronary Stent Registry.
|
|
Academic Article
|
Efficacy and safety of ticagrelor for long-term secondary prevention of atherothrombotic events in relation to renal function: insights from the PEGASUS-TIMI 54 trial.
|
|
Academic Article
|
Design and rationale for the Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54 (PEGASUS-TIMI 54) trial.
|
|
Academic Article
|
Pharmacological treatment and current management of peripheral artery disease.
|
|
Academic Article
|
Efficacy and Safety of Ticagrelor Over Time in Patients With Prior MI in PEGASUS-TIMI 54.
|
|
Academic Article
|
Atherothrombotic Risk Stratification and the Efficacy and Safety of Vorapaxar in Patients With Stable Ischemic Heart Disease and Previous Myocardial Infarction.
|
|
Academic Article
|
Left ventricular thrombosis refractory to medical therapy.
|
|
Academic Article
|
New ischemic stroke and outcomes with vorapaxar versus placebo: results from the TRA 2 °P-TIMI 50 trial.
|
|
Academic Article
|
Growth differentiation factor-15 and risk of recurrent events in patients stabilized after acute coronary syndrome: observations from PROVE IT-TIMI 22.
|
|
Academic Article
|
Antithrombotic Therapy and Major Adverse Limb Events in Peripheral Artery Disease: A Step Forward.
|
|
Academic Article
|
Consistent platelet inhibition with ticagrelor 60 mg twice-daily following myocardial infarction regardless of diabetes status.
|
|
Academic Article
|
Antiplatelet Therapy for Long-term Secondary Prevention After Myocardial Infarction.
|
|
Academic Article
|
Central obesity and cardiovascular outcomes in patients with acute coronary syndrome: observations from the MERLIN-TIMI 36 trial.
|
|
Academic Article
|
The design and rationale for the Dapagliflozin Effect on Cardiovascular Events (DECLARE)-TIMI 58 Trial.
|
|
Academic Article
|
Antithrombotic Therapy in Patients With Peripheral Artery Disease.
|
|
Academic Article
|
Potent P2Y12 Inhibitors in Men Versus Women: A Collaborative Meta-Analysis of Randomized Trials.
|
|
Academic Article
|
Frequency, Predictors, and Impact of Combined Antiplatelet Therapy on Venous Thromboembolism in Patients With Symptomatic Atherosclerosis.
|
|
Academic Article
|
Acute Limb Ischemia and Outcomes With Vorapaxar in Patients With Peripheral Artery Disease: Results From the Trial to Assess the Effects of Vorapaxar in Preventing Heart Attack and Stroke in Patients With Atherosclerosis-Thrombolysis in Myocardial Infarction 50 (TRA2°P-TIMI 50).
|
|
Academic Article
|
Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk).
|
|
Academic Article
|
Appropriate secondary prevention and clinical outcomes after acute myocardial infarction according to atherothrombotic risk stratification: The FAST-MI 2010 registry.
|
|
Academic Article
|
Prevalence and Outcomes of Polyvascular (Coronary, Peripheral, or Cerebrovascular) Disease in Patients With Diabetes Mellitus (From the SAVOR-TIMI 53 Trial).
|
|
Academic Article
|
Polyvascular disease, type 2 diabetes, and long-term vascular risk: a secondary analysis of the IMPROVE-IT trial.
|
|
Academic Article
|
Pharmacokinetic-pharmacodynamic modelling of platelet response to ticagrelor in stable coronary artery disease and prior myocardial infarction patients.
|
|
Academic Article
|
Efficacy and safety of more potent antiplatelet therapy with vorapaxar in patients with impaired renal function.
|
|
Academic Article
|
Atherothrombotic risk stratification after acute myocardial infarction: The Thrombolysis in Myocardial Infarction Risk Score for Secondary Prevention in the light of the French Registry of Acute ST Elevation or non-ST Elevation Myocardial Infarction registries.
|
|
Academic Article
|
Lorcaserin and Renal Outcomes in Obese and Overweight Patients in the CAMELLIA-TIMI 61 Trial.
|
|
Academic Article
|
Vorapaxar for secondary prevention in the elderly with peripheral artery disease: Insights from the TRA 2°P-TIMI 50 trial.
|
|
Academic Article
|
Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus.
|
|
Academic Article
|
Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction.
|
|
Academic Article
|
Outcome associated with prescription of cardiac rehabilitation according to predicted risk after acute myocardial infarction: Insights from the FAST-MI registries.
|
|
Academic Article
|
Efficacy and safety with ticagrelor in patients with prior myocardial infarction in the approved European label: insights from PEGASUS-TIMI 54.
|
|
Academic Article
|
Myocarditis in the Setting of Cancer Therapeutics: Proposed Case Definitions for Emerging Clinical Syndromes in Cardio-Oncology
|
|
Academic Article
|
Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study.
|
|
Academic Article
|
Long-term ticagrelor for secondary prevention in patients with prior myocardial infarction and no history of coronary stenting: insights from PEGASUS-TIMI 54.
|
|
Academic Article
|
Tackling Elevated Risk in PAD: Focus on Antithrombotic and Lipid Therapy for PAD.
|
|
Academic Article
|
Effect of vorapaxar on cardiovascular and limb outcomes in patients with peripheral artery disease with and without coronary artery disease: Analysis from the TRA 2°P-TIMI 50 trial.
|
|
Academic Article
|
The Pathobiology of Acute Limb Ischemic Events and Stent Failure in Peripheral Artery Disease: A Step in the Right Direction.
|
|
Academic Article
|
Rivaroxaban in Peripheral Artery Disease after Revascularization.
|
|
Academic Article
|
The Effect of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition on the Risk of Venous Thromboembolism.
|
|
Academic Article
|
No Significant Relationship Between Ticagrelor and Sleep Apnea in Large, Randomized, Blinded Trials.
|
|
Academic Article
|
Gut Microbiota-Dependent Trimethylamine N-oxide and Cardiovascular Outcomes in Patients With Prior Myocardial Infarction: A Nested Case Control Study From the PEGASUS-TIMI 54 Trial.
|
|
Academic Article
|
Caffeinated Beverage Intake, Dyspnea With Ticagrelor, and Cardiovascular Outcomes: Insights From the PEGASUS-TIMI 54 Trial.
|
|
Academic Article
|
Antithrombotic strategies for patients with coronary and lower extremity peripheral artery diseases: a narrative review.
|
|
Academic Article
|
Contemporary Review of Antithrombotic Therapy in Peripheral Artery Disease.
|
|
Academic Article
|
Rivaroxaban and Aspirin in Peripheral Artery Disease Lower Extremity Revascularization: Impact of Concomitant Clopidogrel on Efficacy and Safety.
|
|
Academic Article
|
New clues for optimal diagnosis and treatment of an old foe: the acute aortic syndrome.
|
|
Academic Article
|
Long-term safety of drug-coated devices for peripheral revascularisation.
|
|
Academic Article
|
Predictors, Type, and Impact of Bleeding on the Net Clinical Benefit of Long-Term Ticagrelor in Stable Patients With Prior Myocardial Infarction.
|
|
Academic Article
|
Sex, Permanent Drug Discontinuation, and Study Retention in Clinical Trials: Insights From the TIMI trials.
|
|
Academic Article
|
Incidence of Major Atherothrombotic Vascular Events among Patients with Peripheral Artery Disease after Revascularization.
|
|
Academic Article
|
Treatment-Dose LMWH versus Prophylactic/Intermediate Dose Heparins in High-Risk COVID-19 Inpatients: Rationale and Design of the HEP-COVID Trial.
|
|
Academic Article
|
Cardiovascular Biomarkers and Heart Failure Risk in Stable Patients With Atherothrombotic Disease: A Nested Biomarker Study From TRA 2°P-TIMI 50.
|
|
Academic Article
|
Cardiac mortality in patients randomised to elective coronary revascularisation plus medical therapy or medical therapy alone: a systematic review and meta-analysis.
|
|
Academic Article
|
Total Ischemic Event Reduction With Rivaroxaban After Peripheral Arterial Revascularization in the VOYAGER PAD Trial.
|
|
Academic Article
|
Impact of chronic kidney disease on hemoglobin among patients with peripheral artery disease treated with P2Y12 inhibitors: Insights from the EUCLID trial.
|
|
Academic Article
|
Diabetes Mellitus and Risk Stratification After Peripheral Artery Revascularization.
|
|
Academic Article
|
Effectiveness of Blood Lipid Management in Patients With Peripheral Artery Disease.
|
|
Academic Article
|
Supervised Exercise Therapy for Symptomatic Peripheral Artery Disease Among Medicare Beneficiaries Between 2017 and 2018: Participation Rates and Outcomes.
|
|
Academic Article
|
Long-Term Ticagrelor in Patients With Prior Coronary Stenting in the PEGASUS-TIMI 54 Trial.
|
|
Academic Article
|
Efficacy and Safety of Therapeutic-Dose Heparin vs Standard Prophylactic or Intermediate-Dose Heparins for Thromboprophylaxis in High-risk Hospitalized Patients With COVID-19: The HEP-COVID Randomized Clinical Trial.
|
|
Academic Article
|
Efficacy and Safety of Vorapaxar by Intensity of Background Lipid-Lowering Therapy in Patients With Peripheral Artery Disease: Insights From the TRA2P-TIMI 50 Trial.
|
|
Academic Article
|
Extended dual antiplatelet therapy with ticagrelor 60?mg in patients with prior myocardial infarction: The design of ALETHEIA, a multi-country observational study.
|
|
Academic Article
|
Low-dose rivaroxaban plus aspirin in older patients with peripheral artery disease undergoing acute limb revascularization: insights from the VOYAGER PAD trial.
|
|
Academic Article
|
Low-dose rivaroxaban and aspirin among patients with peripheral artery disease: a meta-analysis of the COMPASS and VOYAGER trials.
|
|
Academic Article
|
Challenges of long-term dual antiplatelet therapy use following acute coronary syndromes.
|
|
Academic Article
|
Rationale and design of a study to assess the safety and efficacy of rNAPc2 in COVID-19: the Phase 2b ASPEN-COVID-19 trial.
|
|
Academic Article
|
Effect of Anticoagulant Therapy for 6 Weeks vs 3 Months on Recurrence and Bleeding Events in Patients Younger Than 21 Years of Age With Provoked Venous Thromboembolism: The Kids-DOTT Randomized Clinical Trial.
|
|
Academic Article
|
Prevention of arterial and venous thrombotic events in symptomatic peripheral arterial disease patients after lower extremity revascularization in the VOYAGER PAD trial: Dual anticoagulant/antiplatelet regimen vs antiplatelet therapy alone.
|
|
Academic Article
|
Prospective Cardiovascular Surveillance of Immune Checkpoint Inhibitor-Based Combination Therapy in Patients With Advanced Renal Cell Cancer: Data From the Phase III JAVELIN Renal 101 Trial.
|
|
Academic Article
|
Improvement in walking impairment following surgical and endovascular revascularization: Insights from VOYAGER PAD.
|
|
Academic Article
|
Society for Vascular Surgery appropriate use criteria for management of intermittent claudication.
|
|
Academic Article
|
Total Cardiovascular and Limb Events and the Impact of Polyvascular Disease in Chronic Symptomatic Peripheral Artery Disease.
|
|
Academic Article
|
Sex-Based Differences in Outcomes Following Peripheral Artery Revascularization: Insights From VOYAGER PAD.
|
|
Academic Article
|
Cognitive behavioral therapy delivered via digital mobile application for the treatment of type 2 diabetes: Rationale, design, and baseline characteristics of a randomized, controlled trial.
|
|
Academic Article
|
Epidemiology of heart failure hospitalization in patients with stable atherothrombotic disease: Insights from the TRA 2°P-TIMI 50 trial.
|
|
Academic Article
|
The prognostic implications of cardiac troponin in Type A aortic dissection and the challenge of understanding therapeutic consequences.
|
|
Academic Article
|
2022 ACC Expert Consensus Decision Pathway for Integrating Atherosclerotic Cardiovascular Disease and Multimorbidity Treatment: A Framework for Pragmatic, Patient-Centered Care: A Report of the American College of Cardiology Solution Set Oversight Committee.
|
|
Academic Article
|
Uptake of Newer Guideline-Directed Therapies in Heart Failure Patients With Diabetes or Chronic Kidney Disease.
|
|
Academic Article
|
Efficacy and safety of rivaroxaban versus placebo after lower extremity bypass surgery: A post hoc analysis of a "CASPAR like" outcome from VOYAGER PAD.
|
|
Academic Article
|
Tradeoffs in Approach to PAD Revascularization: Shared Decision Making in the Spotlight.
|
|
Academic Article
|
Patient selection for long-term secondary prevention with ticagrelor: insights from PEGASUS-TIMI 54.
|
|
Academic Article
|
Randomized, Controlled Trial of a Digital Behavioral Therapeutic Application to Improve Glycemic Control in Adults With Type 2 Diabetes.
|
|
Academic Article
|
Randomized, Placebo-Controlled Phase 2b Study to Evaluate the Safety and Efficacy of Recombinant Human Lecithin Cholesterol Acyltransferase in Acute ST-Segment-Elevation Myocardial Infarction: Results of REAL-TIMI 63B.
|
|
Academic Article
|
Influence of body weight and body mass index on the chronic pharmacokinetic and pharmacodynamic responses to clinically available doses of ticagrelor in patients with chronic coronary syndromes.
|
|
Academic Article
|
International Perspectives on the Impact of the COVID-19 Pandemic on Adherence to Prescribed Dual Antiplatelet Therapy: A Window Into Acute Cardiovascular Care.
|
|
Academic Article
|
Medical Therapy for Secondary Prevention of Atherothrombotic Events in Peripheral Artery Disease.
|
|
Academic Article
|
Rivaroxaban in patients with symptomatic peripheral artery disease after lower extremity bypass surgery with venous and prosthetic conduits.
|
|
Academic Article
|
Guideline-Directed Medical Therapy in PAD: Time to Step on the Gas.
|
|
Academic Article
|
Sex differences in guideline-directed medical therapy in 2021-22 among patients with peripheral artery disease.
|
|
Academic Article
|
Antithrombotic Therapy in Peripheral Artery Disease: Current Evidence and Future Directions.
|
|
Academic Article
|
Treatment of Cancer-Associated Thrombosis: Recent Advances, Unmet Needs, and Future Direction.
|
|
Academic Article
|
Major cardiovascular events after COVID-19, event rates post-vaccination, antiviral or anti-inflammatory therapy, and temporal trends: Rationale and methodology of the CORONA-VTE-Network study.
|
|
Academic Article
|
Effects of Elective Coronary Revascularization vs Medical Therapy Alone on Noncardiac Mortality: A Meta-Analysis.
|
|
Academic Article
|
Characteristics and outcomes in patients with a prior myocardial infarction treated with extended dual antiplatelet therapy with ticagrelor 60 mg: findings from ALETHEIA, a multi-country observational study.
|
|
Academic Article
|
Rivaroxaban Plus Aspirin Versus Aspirin Alone After Endovascular Revascularization for Symptomatic PAD: Insights From VOYAGER PAD.
|
|
Academic Article
|
Drug-Eluting Resorbable Scaffold versus Angioplasty for Infrapopliteal Artery Disease.
|
|
Academic Article
|
Antithrombotic Prophylaxis with Rivaroxaban in Patients with Prehospital COVID-19: A Meta-analysis of Two Placebo-Controlled Trials.
|
|
Academic Article
|
Disparities in Diagnosis, Treatment, and Outcomes of Peripheral Artery Disease: JACC Scientific Statement.
|
|
Academic Article
|
Lipoprotein(a) and Benefit of Antiplatelet Therapy: Insights from the PEGASUS-TIMI 54 Trial.
|
|
Academic Article
|
Recapturing the Team Approach to Vascular Care.
|
|
Academic Article
|
Optimizing LDL-cholesterol management in ACS patients: Breaking inertia and implementing intensified therapies.
|
|
Academic Article
|
Low-Dose Rivaroxaban Plus Aspirin in Patients With Peripheral Artery Disease Undergoing Lower Extremity Revascularization With and Without Concomitant Coronary Artery Disease: Insights From VOYAGER PAD.
|
|
Academic Article
|
Clonal hematopoiesis, cardiovascular events and treatment benefit in 63,700 individuals from five TIMI randomized trials.
|
|
Academic Article
|
Methods, design, and initial results of an angiographic core lab from VOYAGER-PAD.
|
|
Academic Article
|
Duration of anticoagulation for venous thromboembolism in pediatric patients: Evaluation of the Duration of Therapy for Thrombosis in Children (Kids-DOTT) trial outcomes at 2 years.
|
|
Academic Article
|
Early treatment with inhibitors of P2Y12 receptor in patients with ST-segment elevation myocardial infarction - 2023 ESC recommendations and scientific evidence. Is clinical evidence sufficient to suggest a move towards precision medicine? The ELECTRA-SIRIO 2 investigators' viewpoint.
|
|
Academic Article
|
Vericiguat Global Study in Participants with Chronic Heart Failure: Design of the VICTOR trial.
|
|
Academic Article
|
Low-Dose Rivaroxaban Plus Aspirin in Fragile Patients After Lower Extremity Revascularization.
|
|
Academic Article
|
Demystifying the Contemporary Role of 12-Month Dual Antiplatelet Therapy After Acute Coronary Syndrome.
|
|
Academic Article
|
Antithrombotic Therapy in Patients Undergoing Peripheral Artery Interventions.
|
|
Academic Article
|
Long-term Antithrombotic Therapy in Patients With Chronic Coronary Syndrome: An Updated Review of Current Evidence.
|
|
Academic Article
|
Early combination lipid-lowering therapy is associated with greater achievement of goal LDL-C: Insights from the OPTIMIZE PAD-1 trial.
|
|
Academic Article
|
Quantitative Benefit-Risk Evaluation of Rivaroxaban in Patients After Peripheral Arterial Revascularization: The VOYAGER PAD Trial.
|
|
Academic Article
|
Limb Outcomes With Ticagrelor Plus Aspirin in Patients With Diabetes Mellitus and Atherosclerosis.
|
|
Academic Article
|
Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE): a phase 3b, double-blind, randomised, placebo-controlled trial.
|
|
Academic Article
|
Anticoagulation and Antiplatelet Therapy for Atrial Fibrillation and Stable Coronary Disease: Meta-Analysis of Randomized Trials.
|
|
Academic Article
|
BEST-CLI International Collaborative: planning a better future for patients with chronic limb-threatening ischaemia globally.
|
|
Academic Article
|
Unplanned Index Limb Revascularization With Rivaroxaban Versus Placebo in Patients With Critical Limb-Threatening Ischemia After Endovascular and Surgical Treatment: Insights From VOYAGER PAD.
|
|
Academic Article
|
Current Gaps in the Provision of Safe and Effective Anticoagulation in Atrial Fibrillation and the Potential for Factor XI-Directed Therapeutics.
|
|
Academic Article
|
Management of Peripheral Arterial Disease: Lifestyle Modifications and Medical Therapies.
|
|
Academic Article
|
Medical Therapy for Peripheral Artery Disease.
|
|
Academic Article
|
Baseline characteristics of contemporary trial participants with heart failure and reduced ejection fraction: The VICTOR trial.
|
|
Academic Article
|
Heart failure with preserved ejection fraction therapeutics: in search of the pillars.
|
|
Academic Article
|
Design and baseline characteristics of the STRIDE trial: evaluating semaglutide in people with symptomatic peripheral artery disease and type 2 diabetes.
|
|
Academic Article
|
Efficacy and Safety of P2Y12 monotherapy vs standard DAPT in patients undergoing percutaneous coronary intervention: meta-analysis of randomized trials.
|
|
Academic Article
|
Drug-Eluting Resorbable Scaffold Versus Balloon Angioplasty for Below-the-Knee Peripheral Artery Disease: 2-Year Results From the LIFE-BTK Trial.
|
|
Academic Article
|
First myocardial infarction: risk factors, symptoms, and medical therapy.
|
|
Academic Article
|
Role of Lipids and Lipid Management Therapy Among Patients With Peripheral Artery Disease: A Reappraisal of the Current Evidence and Future Directions.
|
|
Academic Article
|
Vericiguat in patients with chronic heart failure and reduced ejection fraction (VICTOR): a double-blind, placebo-controlled, randomised, phase 3 trial.
|
|
Academic Article
|
Anatomic profile of arterial occlusive disease in the BEST-CLI trial.
|
|
Academic Article
|
Digital Therapeutic Based Randomized Investigation to Improve Glycemic Control in Patients With Type 2 Diabetes and Residual Hyperglycemia on Stable Medical Therapy: Rationale, Design, and Baseline Characteristics of the BRIGHT Trial.
|
|
Academic Article
|
Effect of Vericiguat on Total Heart Failure Events in Compensated Outpatients With HFrEF: Insights From VICTOR.
|
|
Academic Article
|
Sex Differences in Effectiveness of Semaglutide in Patients With Peripheral Artery Disease: The STRIDE Trial.
|
|
Academic Article
|
Vericiguat for patients with heart failure and reduced ejection fraction across the risk spectrum: an individual participant data analysis of the VICTORIA and VICTOR trials.
|
|
Academic Article
|
Peripheral artery disease.
|